National Pregnancy Registry for Atypical Antipsychotics
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 800
Summary
- Conditions
- Bipolar Disorder
- Depression
- Schizoaffective Disorder
- Schizophrenia
- Use of Atypical Antipsychotics During Pregnancy
- Design
- Observational Model: Case-ControlTime Perspective: Prospective
Participation Requirements
- Age
- Between 18 years and 45 years
- Gender
- Only males
Description
The National Pregnancy Registry for Atypical Antipsychotics is dedicated to evaluating the safety of atypical antipsychotic medications that may be taken by women during pregnancy to treat a wide range of mood, anxiety, or psychiatric disorders. The primary goal of this Registry is to determine the ...
The National Pregnancy Registry for Atypical Antipsychotics is dedicated to evaluating the safety of atypical antipsychotic medications that may be taken by women during pregnancy to treat a wide range of mood, anxiety, or psychiatric disorders. The primary goal of this Registry is to determine the frequency of major malformations, such as heart defects, cleft lip, or neural tube defects, in infants exposed to atypical antipsychotics during pregnancy. We are currently studying the following medications: Abilify (aripiprazole) Aristada (aripiprazole lauroxil) Clozaril (clozapine) Fanapt (iloperidone) Geodon (ziprasidone) Invega (paliperidone) Latuda (lurasidone) Rexulti (brexpiprazole) Risperdal (risperidone) Saphris (asenapine) Seroquel (quetiapine) Zyprexa (olanzapine) Vraylar (cariprazine)
Tracking Information
- NCT #
- NCT01246765
- Collaborators
- Sunovion
- Alkermes, Inc.
- Otsuka America Pharmaceutical
- Teva Pharmaceutical Industries, Ltd.
- Sage Therapeutics
- Investigators
- Principal Investigator: Lee S Cohen, MD Massachusetts General Hospital